The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...
Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback